Suppr超能文献

类风湿关节炎与心血管风险:基于意大利风湿病学会RECORD研究的回顾性匹配队列分析

Rheumatoid Arthritis and Cardiovascular Risk: Retrospective Matched-Cohort Analysis Based on the RECORD Study of the Italian Society for Rheumatology.

作者信息

Argnani Lisa, Zanetti Anna, Carrara Greta, Silvagni Ettore, Guerrini Giulio, Zambon Antonella, Scirè Carlo Alberto

机构信息

Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.

Epidemiology Unit, Italian Society for Rheumatology, Milan, Italy.

出版信息

Front Med (Lausanne). 2021 Oct 5;8:745601. doi: 10.3389/fmed.2021.745601. eCollection 2021.

Abstract

Rheumatoid arthritis (RA) is associated with an increase in cardiovascular (CV) risk. This issue maybe not only explained by a genetic component, as well as by the traditional CV risk factors, but also by an underestimation and undertreatment of concomitant CV comorbidities. This was a retrospective matched-cohort analysis in the Italian RA real-world population based on the healthcare-administrative databases to assess the CV risk factors and incidence of CV events in comparison with the general population. Persistence and adherence to the CV therapy were also evaluated in both groups. In a RA cohort ( = 21,201), there was a greater prevalence of hypertension and diabetes with respect to the non-RA subjects ( = 249,156) (36.9 vs. 33.4% and 10.2 vs. 9.6%, respectively), while dyslipidemia was more frequent in the non-RA group (15.4 vs. 16.5%). Compared with a non-RA cohort, the patients with RA had a higher incidence of atrial fibrillation (incidence rate ratio, IRR 1.28), heart failure (IRR 1.53), stroke (IRR 1.19), and myocardial infarction (IRR 1.48). The patients with RA presented a significantly lower persistence rate to glucose-lowering and lipid-lowering therapies than the controls (odds ratio, 0.73 [95% 0.6-0.8] and 0.82 [0.8-0.9], respectively). The difference in the adherence to glucose-lowering therapy was significant ( 0.7 [0.6-0.8]), conversely no statistically significant differences emerged regarding the adherence to lipid-lowering therapy ( 0.89 [95% 0.8-1.0]) and anti-hypertensive therapy ( 0.96 [95% 0.9-1.0]). The patients with RA have a higher risk of developing CV events compared with the general population, partially explained by the excess and undertreatment of CV risk factors.

摘要

类风湿关节炎(RA)与心血管(CV)风险增加相关。这个问题可能不仅由遗传因素以及传统的心血管风险因素所解释,还可能是由于对合并的心血管疾病的低估和治疗不足。这是一项基于医疗行政数据库对意大利RA真实世界人群进行的回顾性匹配队列分析,以评估心血管风险因素和心血管事件的发生率,并与普通人群进行比较。同时还评估了两组中对心血管治疗的持续性和依从性。在一个RA队列(n = 21,201)中,与非RA受试者(n = 249,156)相比,高血压和糖尿病的患病率更高(分别为36.9%对33.4%和1,0.2%对9.6%),而非RA组血脂异常更为常见(15.4%对16.5%)。与非RA队列相比,RA患者发生房颤(发病率比,IRR 1.28)、心力衰竭(IRR 1.53)、中风(IRR 1.19)和心肌梗死(IRR 1.48)的发生率更高。RA患者对降糖和降脂治疗的持续率显著低于对照组(优势比分别为0.73 [95% CI 0.6 - 0.8]和0.82 [0.8 - 0.9])。降糖治疗的依从性差异显著(0.7 [0.6 - 0.8]),相反,降脂治疗(0.89 [95% CI 0.8 - 1.0])和抗高血压治疗(0.96 [95% CI 0.9 - 1.0])的依从性没有统计学上的显著差异。与普通人群相比,RA患者发生心血管事件的风险更高,部分原因是心血管风险因素的过多和治疗不足。

相似文献

4
High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors.
Arthritis Rheum. 2001 Dec;44(12):2737-45. doi: 10.1002/1529-0131(200112)44:12<2737::AID-ART460>3.0.CO;2-%23.
8
Incidence and Management of Cardiovascular Risk Factors in Psoriatic Arthritis and Rheumatoid Arthritis: A Population-Based Study.
Arthritis Care Res (Hoboken). 2017 Jan;69(1):51-57. doi: 10.1002/acr.23094. Epub 2016 Nov 28.

引用本文的文献

3
4
Incidence Rate of Cardiovascular Events in Rheumatoid Arthritis: An Observational Cohort Study in Saudi Arabia.
J Multidiscip Healthc. 2024 Jul 12;17:3357-3370. doi: 10.2147/JMDH.S459555. eCollection 2024.
5
Anti-apolipoprotein A-1 IgG, incident cardiovascular events, and lipid paradox in rheumatoid arthritis.
Front Cardiovasc Med. 2024 May 20;11:1386192. doi: 10.3389/fcvm.2024.1386192. eCollection 2024.
6
Association between rheumatoid arthritis and atrial fibrillation: A systematic review and meta-analysis.
J Arrhythm. 2024 Jan 23;40(2):203-213. doi: 10.1002/joa3.12995. eCollection 2024 Apr.
9
Evolocumab prevents atrial fibrillation in rheumatoid arthritis rats through restraint of PCSK9 induced atrial remodeling.
J Adv Res. 2024 Jul;61:211-221. doi: 10.1016/j.jare.2023.09.007. Epub 2023 Sep 12.
10
Triterpenes as Potential Drug Candidates for Rheumatoid Arthritis Treatment.
Life (Basel). 2023 Jul 5;13(7):1514. doi: 10.3390/life13071514.

本文引用的文献

3
The lipid paradox in rheumatoid arthritis: the dark horse of the augmented cardiovascular risk.
Rheumatol Int. 2020 Aug;40(8):1181-1191. doi: 10.1007/s00296-020-04616-2. Epub 2020 Jun 10.
4
Atherosclerotic cardiovascular disease prevention in rheumatoid arthritis.
Nat Rev Rheumatol. 2020 Jul;16(7):361-379. doi: 10.1038/s41584-020-0428-y. Epub 2020 Jun 3.
7
Is There a Threshold for Medication Adherence? Lessons Learnt From Electronic Monitoring of Drug Adherence.
Front Pharmacol. 2019 Jan 9;9:1540. doi: 10.3389/fphar.2018.01540. eCollection 2018.
8
The effect of rheumatoid arthritis on the risk of cerebrovascular disease and coronary artery disease in young adults.
J Chin Med Assoc. 2018 Sep;81(9):772-780. doi: 10.1016/j.jcma.2018.03.009. Epub 2018 Jun 1.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验